GHK-Cu
Copper tripeptide-1
The Ground Truth Score
four plain questions, never one numberReal for skin, extrapolated by needle
Bottom line
The best-evidenced wellness peptide here for skin, decades of cosmetic research and controlled topical studies, but injectable use rides on that reputation with far less direct human data.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported, not prescribed.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Discovered in 1973 by Dr. Loren Pickart, who identified GHK in human plasma and demonstrated its activity in human tissue studies. Topical human use is well-documented; injectable human use is recent and sparse.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Stimulates collagen synthesis and skin repair; reduces visible aging.
- Speeds wound healing and dampens inflammation.
- Synergizes powerfully with red-light therapy.
The data behind each bullet
What actually backs it
Improves skin and stimulates collagen.
Topical GHK-Cu has the most human support of any form: post-laser and cosmetic-dermatology studies report faster healing and lower inflammatory markers, alongside decades of cosmetic use. Injectable and anti-aging collagen claims extrapolate from this topical base, which is a real stretch.
GHK-Cu topical skin literature (PubMed search) ↗Speeds wound healing.
Supported by the same topical data and extensive in-vitro work. In gene-database modeling of cultured cells, GHK-Cu shifted the expression of about a third of human genes (a lab-dish finding, not an in-vivo human outcome), and it promotes M2 macrophages and acts as an antioxidant. Note: that gene work is single-origin from Loren Pickart, who founded a company that sells GHK-Cu products, so treat it as real but commercially interested.
Pickart & Margolina 2018 (PMC6073405) ↗Synergizes with red light.
Dr. Bakri cites topical GHK-Cu plus red light producing large increases in fibroblast viability and growth-factor secretion, compelling, but largely in-vitro and mechanistic rather than from human outcome trials.
Bakri. Enhanced Live formulation ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Best-evidenced of the wellness peptides for skin: GHK-Cu delivers copper and shifts the expression of ~31% of human genes toward repair, stimulating collagen, dampening inflammation, acting as an antioxidant. Strong in cell and topical studies; injectable effects extrapolate from there.
Dosing & handling
What users and clinicians report
Reported, not prescribed. Topical: 1–3% serum daily (well-supported, available over the counter). Injectable (where legal): ~1–2 mg subcutaneously, daily to several times weekly. Dr. Bakri's notable divergence: he treats GHK-Cu as continuous rather than cycled, on the logic that it replenishes an endogenous peptide that declines with age, citing a wide safety margin.
Topical is the evidence-backed route. Injectable figures are early and authority-reported. Not medical advice.
Timing & food
Topical applied daily (often PM, paired with red light); injectable (where legal) daily to a few times weekly. No strict food rule. Dr. Bakri's notable divergence: he treats GHK-Cu as continuous rather than cycled.
Half-life
Short in the bloodstream; applied topically it acts locally over hours. Injectable human pharmacokinetics are not well characterized.
Reconstitution sensitivity
The copper complex is both the active and the hazard, store cold and protected from light. Topical serums are more shelf-stable than a reconstituted injectable, where copper content needs to stay in spec.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Large for topical skincare; a smaller, more honest injectable community.
Consistency
Topical firmness/texture reports converge, but there's a real negative cluster (the 'copper uglies') and injectable is quieter.
Source credibility
Among the most influencer-contaminated spaces; the credible signal lands on 'useful supporting ingredient, not a miracle.'
- Topical skin and hair improvement is widely and consistently reported, the best-substantiated of any wellness peptide here.
- Injectable users report skin, hair, and recovery benefits, but the record is much thinner.
- Well-tolerated topically; injectable site irritation is occasionally reported.
Placebo risk, Moderate
Skin and hair changes are partly visible and objective, and topical use has real human data, so placebo risk is lower than most, but the 'glow' feeling still inflates reports.
Risk panel
What could go wrong
Adverse events
Topical use is well-established and benign. Injectable adverse events are poorly characterized simply because injectable human use is new.
Theoretical concerns
Copper toxicity is a theoretical concern at high injected doses; topical exposure is far below that threshold.
Contraindications
Wilson's disease or copper-overload conditions (copper content). Caution with injectable use given thin data.
Honest unknowns
Long-term injectable safety, and whether injectable efficacy matches the well-documented topical effect.
Confound watch
Skin improvement is heavily confounded, retinoids, sunscreen, red light, microneedling, hydration and sleep all move the same needle. GHK-Cu users typically run several of these at once.
History
Discovery → first use → status
Heads up: the legal status is moving (2026)
This one got put on the FDA's Category 2 'do not compound' list back in 2023. In April 2026 the FDA moved to pull it back off that list, and there's a July 2026 advisory meeting weighing whether it can be legally compounded again. None of that is final, and none of it makes anything proven or safe. It just means the legal picture is changing fast, so check the date on anything you read about whether this is allowed.
FDA peptide compounding update, 2026 ↗- 1973Dr. Loren Pickart discovers GHK in human plasma.
- 1980s–2010sGHK-Cu becomes a staple of cosmetic skincare; hundreds of topical studies accumulate.
- Sept 2023FDA prohibits injectable GHK-Cu for commercial compounding (Category 2).
- 2024Multicenter topical post-laser study quantifies healing and anti-inflammatory effects.
- Apr 23 2026Removed from Category 2; some pharmacies resume injectable production.
Verification
The COA standard, applied
For topical, a straightforward COA confirming GHK-Cu identity and concentration is enough. For injectable, apply the full standard. HPLC ≥98%, mass-spec identity, LAL endotoxin from Janoshik or Finnrick, and verify copper content is within spec, since the chelated copper is both the active and the hazard.
The full verification standard →Sources
Where this comes from
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.